Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

1.480 -0.150 (-9.20%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd

< Previous 1 2 3 4 Next >
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Investor and Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
Via ACCESSWIRE
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
Via ACCESSWIRE
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
Via ACCESSWIRE
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Via ACCESSWIRE
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
Via ACCESSWIRE
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023
Via ACCESSWIRE
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
Via ACCESSWIRE
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
Via ACCESSWIRE
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles
Via ACCESSWIRE
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo
Via ACCESSWIRE
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.